BLCO
vs
S&P 500
Over the past 12 months, BLCO has underperformed S&P 500, delivering a return of 11% compared to the S&P 500's 25% growth.
Stocks Performance
BLCO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
Hoya Corp
TSE:7741
|
||
CH |
Alcon AG
SIX:ALC
|
||
DK |
Coloplast A/S
CSE:COLO B
|
||
US |
Align Technology Inc
NASDAQ:ALGN
|
||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
|
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
||
UK |
ConvaTec Group PLC
LSE:CTEC
|
||
US |
Merit Medical Systems Inc
NASDAQ:MMSI
|
||
CH |
Ypsomed Holding AG
SIX:YPSN
|
Performance Gap
BLCO vs S&P 500
JP |
Hoya Corp
TSE:7741
|
||
CH |
Alcon AG
SIX:ALC
|
||
DK |
Coloplast A/S
CSE:COLO B
|
||
US |
Align Technology Inc
NASDAQ:ALGN
|
||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
|
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
||
UK |
ConvaTec Group PLC
LSE:CTEC
|
||
US |
Merit Medical Systems Inc
NASDAQ:MMSI
|
||
CH |
Ypsomed Holding AG
SIX:YPSN
|
Performance By Year
BLCO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
Hoya Corp
TSE:7741
|
||
CH |
Alcon AG
SIX:ALC
|
||
DK |
Coloplast A/S
CSE:COLO B
|
||
US |
Align Technology Inc
NASDAQ:ALGN
|
||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
|
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
||
UK |
ConvaTec Group PLC
LSE:CTEC
|
||
US |
Merit Medical Systems Inc
NASDAQ:MMSI
|
||
CH |
Ypsomed Holding AG
SIX:YPSN
|
Competitors Performance
Bausch + Lomb Corp vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CA |
A
|
Advance Lithium Corp
XTSX:AALI
|
|
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Bausch + Lomb Corp
Glance View
Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery. Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.